zinc finger protein X-linkedGenealiases: MRXS37 · ZNF926
Q-omics provides the consensus-scored ZFX profile across patient tissues and cancer cell-line models. ZFX expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZFX is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZFX RNA expression shows 20,896 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where ZFX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFX survival associations across molecular data types. ZFX RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFX RNA expression–survival associations across cancer types. High ZFX expression shows unfavorable associations in ACC, KICH, CESC, LGG and UVM, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZFX RNA expression.
This table summarizes ZFX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZFX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFX shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in HNSC, LIHC and CHOL. The THCA box plot shows higher ZFX RNA expression in normal versus tumor tissue (log2 FC = −0.695, t-test p < 0.001).
This table shows molecular features associated with ZFX in patient tissues and cancer cell lines. In patient samples, ZFX shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
